Combined Injectable Treatment for HIV and OUD (CHOICE)
Human Immunodeficiency Virus, Opioid Use Disorder
About this trial
This is an interventional treatment trial for Human Immunodeficiency Virus
Eligibility Criteria
Inclusion Criteria: 18-65 years of age HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay Current diagnosis of OUD according to DSM-5 Able to understand and speak English and to provide written and verbal informed consent Participants recruited through RIDOC will have an additional requirement of anticipated release from jail/prison within 6 months. Exclusion Criteria: Currently pregnant, breastfeeding, planning to become pregnant or breastfeed during the study period Coinfection of Hepatitis B or plans to get treated for Hepatitis C during the study period
Sites / Locations
- Rhode Island HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Preliminary Test of Combined LAI Treatment
The combined injectable treatment includes a dual-administration of rilpivirine (CAB/RPV) "cabenuva" for HIV and extended-release buprenorphine (XR-B) "sublocade" for OUD.